Intravenous Glutathione - Redding / Northern California

Antioxidants are substances that NEUTRALIZE toxic waste, known scientifically as “free radicals”, which are produced during the normal course of metabolism in the human body. Mainly produced in the Liver, a substance called GLUTATHIONE is said to be the most potent natural antioxidant found in the human body. Intravenous Glutathione can be exceptionally helpful to aid the body in removing excessive amounts of poisons and toxic waste. This is especially the case when the body is in a compromised state of health. Examples of this would include:

• 1. Excessive ingestion of poisons/medications (eg. Tylenol overdose)
• 2. As a compliment to conventional cancer treatment (along with high dose Vitamin C infusions)
• 3. As an aid in ridding the body of toxic heavy metals and environmentally-induced illnesses
• 4. Neurodegenerative diseases, such as Parkinson's disease and Multiple Sclerosis.

Dr. Daniel Goodman, MD a board certified anesthesiologist for over 25 years is an expert in the field of intravenous medicine. He has been providing Glutathione infusions since 2012 to patients in Redding, CA and the Northern California region.

Parkinson's research: Glutathione is thought to be depleted in the brains of patients with Parkinson’s disease. Glutathione is vital to protect brain cells from the excessive build up of toxic "free radicals”. In addition, Glutathione enhances the function of other antioxidant compounds by keeping them refreshed. In 1996, a group of researchers from Italy reported that intravenous Glutathione, given twice a day for one month, resulted in a significant improvement in the symptoms of Parkinson’s patients. After the Glutathione administration was stopped, the therapeutic effect was noted to last for as long as 2-4 months. Even one dose of Intravenous Glutathione, given in our Redding/Northern California office, has been noted to provide up to one week of improvement in motor function and overall well being.

Cancer Research: A randomized pilot trial with 45 participants investigated the effect of glutathione to prevent complication for radiation therapy. Patients were administered 1200 mg glutathione or saline placebo intravenously 15 minutes prior to pelvic radiotherapy. Patients receiving glutathione suffered from less post-therapy diarrhea (28% compared to 52% of controls) and were more likely to complete the treatment cycle (71% to 52%).

A double-blind trial studied the neuroprotective effect of intravenous glutathione given along with standard chemotherapy in the treatment for stomach cancer. After nine weeks of treatment, none of the 24 patients who were receiving glutathione, had developed neuropathy symptoms. In stark contrast, 16 of the 18 patients that did NOT receive glutathione, did develop significant neuropathy. In addition, a trend toward greater chemotherapy effectiveness was seen in the patients receiving the glutathione treatment.

One trial involving 79 patients with ovarian cancer found that the IV administration of glutathione prior to chemotherapy treatment (with a standardized chemotherapy combination) led to greater tumor destruction and reduced toxicity compared to patients who were given the same chemotherapeutic agents but without the glutathione. Another trial using the same glutathione dose with the same combination chemotherapy found no cases of nephrotoxicity in 20 patients.

Bibliography: Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1159-70. Dalhoff K, Ranek L, Mantoni M, Poulsen, HE. Glutathione treatment of hepatocellular carcinoma. Liver 1992;12:341-343. Novi AM. Regression of aflatoxin B1-induced hepatocellular carcinomas by reduced glutathione. Science 1981;212:541-542. Kidd PM. Glutathione: systemic protectant against oxidative and free radical damage. Altern Med Rev 1997;2:155-176. DeMaria D, Falchi AM, Venturino P. Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer. Tumori 1992;78:374-376. Meijer C, Mulder NH, de Vries EGE. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 1990;17:389-407. Smyth JF, Bowman A, Parren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997;8:569-573. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 1996;6:415-419. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993;4:55-61. Locatelli MC, D'Antonia A, Lablanca R, et al. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 1993;79:37-39.